23andMe

23andMe is Looking for Individuals Who've Recovered From COVID-19 Hospitalizations to Participate in New Study

Retrieved on: 
Tuesday, May 26, 2020
Applied genetics, Branches of biology, Genetics, 23andMe, Biotechnology companies

To help gather more insights, 23andMe has launched a research study to help determine whether genetics may play a role.

Key Points: 
  • To help gather more insights, 23andMe has launched a research study to help determine whether genetics may play a role.
  • Recently, 23andMe scientists, Joyce Tung and Adam Auton, participated in a Satellite Media Tour to discuss initial results from the study and what they hope to find.
  • He manages a group within the Research team with a focus on statistical and population genetics.
  • It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology.

Global Personalized Nutrition Markets 2020-2026 with BASF, Royal DSM, Nestle, Lonza and IBM Dominating

Retrieved on: 
Tuesday, April 21, 2020
Branches of biology, Nutrition, Applied genetics, Genetics, Articles, 23andMe, Obesity

Substantial marketed products are being produced and provided by startup companies in this domain including 23andMe, Bulu Box, DayTwo and FitGenie.

Key Points: 
  • Substantial marketed products are being produced and provided by startup companies in this domain including 23andMe, Bulu Box, DayTwo and FitGenie.
  • The introduction of artificial intelligence-based algorithms to better track health data on a routine basis is also increasingly changing the various aspects of customized nutrition.
  • Previously, personalized nutrition research was focused on the integration of genetic data, but today various other parameters that give a more comprehensive outcome of the dietary behavior of the individual are also reliable.
  • It may help in curbing the high food intake which contributes to obesity and weight gain.

TWO NIL Engages North 6th Agency As Public Relations Agency Of Record

Retrieved on: 
Tuesday, April 14, 2020
Academic disciplines, Articles, Branches of biology, Groupon, 23andMe, Accountability

NEW YORK, April 14,2020 /PRNewswire/ -- North 6th Agency (N6A), the Outcome Relations Agency,today announced that it has partnered with TWO NIL as public relations agency of record.

Key Points: 
  • NEW YORK, April 14,2020 /PRNewswire/ -- North 6th Agency (N6A), the Outcome Relations Agency,today announced that it has partnered with TWO NIL as public relations agency of record.
  • TWO NIL's clients include 23andMe, Blue Apron, RxSense, Bombas, Groupon, and many other leading brands across e-commerce, direct-to-consumer, gaming, entertainment and media categories.
  • "We felt great synergies with N6A and with their service model, which challenges the legacy public relations category by bringing accountability and alignment with business outcomes," said Mark Zamuner, CEO of TWO NIL.
  • N6A will implement and execute on multiple outcome-based public relations campaigns to support TWO NIL on their desired business outcomes, including competitive awareness, revenue and recruiting outcomes.

Global Genomics Market (2020 to 2027) - Key Players Include Thermo Fisher Scientific, Life Technologies & Affymetrix Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, March 16, 2020
Health, Genetics, Branches of biology, Biology, Medicine, Biotechnology, Applied genetics, Emerging technologies, 23andMe, Personalized medicine, Genomics

The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.

Key Points: 
  • The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.
  • Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
  • Increasing pool of market innovators such as 23andMe, Oxford Nanopore Technologies, and Veritas Genetics that have launched breakthrough genomic technologies in recent years are also contributing toward market development.
  • 23andMe has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has recently received FDA approval for its commercialization.

Genomics Market Size Worth $31.1 Billion by 2027 | CAGR: 7.7%: Grand View Research, Inc.

Retrieved on: 
Wednesday, March 4, 2020
Branches of biology, Medicine, Biology, Biotechnology, Emerging technologies, 23andMe, Genomics, Personalized medicine

SAN FRANCISCO, March 4, 2020 /PRNewswire/ -- The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 4, 2020 /PRNewswire/ -- The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period, according to a new report by Grand View Research, Inc.
  • Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
  • Key suggestions from the report:
    Key players of genomics market include 23andMe; F. Hoffmann-La Roche Ltd.; BGI; Myriad Genetics Inc.; Danaher.
  • Grand View Research has segmented the global genomics market on the basis of deliverables, application and technology, end use, and region:

Genomics Market Size Worth $31.1 Billion by 2027 | CAGR: 7.7%: Grand View Research, Inc.

Retrieved on: 
Wednesday, March 4, 2020
Branches of biology, Medicine, Biology, Biotechnology, Emerging technologies, 23andMe, Genomics, Personalized medicine

SAN FRANCISCO, March 4, 2020 /PRNewswire/ -- The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 4, 2020 /PRNewswire/ -- The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period, according to a new report by Grand View Research, Inc.
  • Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
  • Key suggestions from the report:
    Key players of genomics market include 23andMe; F. Hoffmann-La Roche Ltd.; BGI; Myriad Genetics Inc.; Danaher.
  • Grand View Research has segmented the global genomics market on the basis of deliverables, application and technology, end use, and region:

Worldwide Genomics Markets, 2020-2027 - Comprehensive Analysis on the $31.1 Billion-Projected Industry

Retrieved on: 
Wednesday, February 26, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Molecular biology, Applied genetics, Emerging technologies, DNA, 23andMe, Personalized medicine, DNA sequencing, Genomics

The global genomics market is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.

Key Points: 
  • The global genomics market is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.
  • Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
  • 23andMe has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has recently received FDA approval for its commercialization.
  • The company has also begun the commercialization of this technique for newborn's genomic sequencing applications in China in 2017.

Geneanet, the Leading Genealogy Website in Europe, Launches Its DNA Matching Service

Retrieved on: 
Tuesday, February 25, 2020
Branches of biology, Genealogy websites, Applied genetics, Genetics, Academic disciplines, Forensic genetics, Biological databases, MyHeritage, 23andMe, DNA database, Family Tree DNA, DNA profiling

PARIS, Feb. 25, 2020 /PRNewswire/ -- This new beta DNA matching service allows everyone to upload the raw data of a DNA test kit taken from any company, and to compare it to other Geneanet members' DNA data for finding new relatives.

Key Points: 
  • PARIS, Feb. 25, 2020 /PRNewswire/ -- This new beta DNA matching service allows everyone to upload the raw data of a DNA test kit taken from any company, and to compare it to other Geneanet members' DNA data for finding new relatives.
  • Completely free of charge, Geneanet DNA supports DNA data from AncestryDNA, 23andMe, MyHeritage, Family Tree DNA and Living DNA.
  • Two persons who have taken a DNA test with two different companies will be able to find they are related thanks to the Geneanet DNA database.
  • If you have European ancestors, Geneanet is the most informative and fairly priced genealogy website of all.

How Genetic Testing with 23andMe Can Improve Your Health

Retrieved on: 
Thursday, January 30, 2020
Applied genetics, Branches of biology, Genetics, Genealogy websites, Articles, 23andMe, Health

23andMe offers a wealth of reports that provide genetic health information that can help customers be more proactive about their health.

Key Points: 
  • 23andMe offers a wealth of reports that provide genetic health information that can help customers be more proactive about their health.
  • Designed by 23andMe and M/A/R/C Research, researchers asked 23andMe Health + Ancestry customers about the overall impact of their 23andMe experience, regardless of their results.
  • Michelle was inspired to order a 23andMe Health + Ancestry kit to help prepare for any potential genetic health risks, due to several serious health risks running in her family.
  • It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology.

Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee

Retrieved on: 
Friday, December 13, 2019
Branches of biology, Medicine, Biology, Cognitive disorders, Psychiatric diagnosis, Learning disabilities, RTT, Genentech, 23andMe, Biomarker, Frontotemporal dementia, Dementia

Scheller and Sdhof will serve as key R&D leaders supporting the advancement of Alectors research pipeline and proprietary drug discovery platform.

Key Points: 
  • Scheller and Sdhof will serve as key R&D leaders supporting the advancement of Alectors research pipeline and proprietary drug discovery platform.
  • He is currently the Chairman of Research and Development at BridgeBio, and previously held executive leadership positions at 23andMe and Genentech.
  • In a short time, Alector has made tremendous progress with several programs in the clinic, and many more to follow shortly behind.
  • The Companys product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease.